imSAVAR is launched

The EU Horizon 2020 project imSAVARĀ  starts 1th December 2020. The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy safety and efficacy. IZBI will contribute by designing cellular and molecular biomarkers for early detection of adverse effects. imSAVAR brings together more than 20 partners from Europe.